As a result, CD25 loss-of-function in mice is associated with Treg deficiency and widespread autoimmunity. Low dose IL-2 is being evaluated for treatment of autoimmune diseases and has been shown to ...

However, the origin of such Treg defects and their significance in the pathogenesis and treatment of SLE are still poorly understood. Methods Peripheral blood mononuclear cells (PBMC) from 61 patients ...

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius ...

Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to guide regulatory ...

Consequently, multiple CD4+ T cell subsets with effector functions have been implicated in the pathology of SLE, indicating that controlling the differentiation of these CD4+ T cell subsets may be a ...

Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced an ag ...

Imugene has dosed the first Australian subject in a Phase Ib trial of its allogeneic CAR T-cell therapy, azer-cel (azercabtagene zapreleucel).

Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101.

Analyst Judah Frommer of Morgan Stanley maintained a Buy rating on Mural Oncology Plc (MURA – Research Report), retaining the price target of ...

After nabbing an FDA approval last summer for its T-cell lymphoma treatment Lymphir, Citius Oncology is eyeing strategic ...

29, 1984, he infused these back into her bloodstream and inoculated her with higher than typical doses of IL-2 repeatedly, hoping to put her immune system into overdrive. The treatment was difficult.